AACR 2020: Posters on TK1 and AroCell TK 210 ELISA is now online

Two posters at the American Association of Cancer Research 2020 (AACR 2020) on TK1 and AroCell TK 210 ELISA has now been published online.

The content of the posters has previously been released as an abstract and now the complete posters can be read on AACR’s website.

The first poster has the title “Serum Thymidine Kinase 1 levels predict prostate cancer-specific survival” and is based on a study by Teemu Murtola of Tampere University Hospital. The poster describes the use of Thymidine Kinase 1 as a prognostic marker for the progression of prostate cancer after diagnosis.

The second poster's title is “Evaluation of TK1 protein changes using the AroCell TK 210 ELISA in an acute myeloid leukemia (AML) xenograft model during 5-fluoruracil treatment.” by Jagarlamudi KK et al, demonstrates how the immunoassay of Thymidine Kinase 1 can be used to study anti-cancer drug effects in a clinically relevant animal model.

Link to AACR Posters.

Contacts

Michael Brobjer, CEO
Telephone: +46(0)18 50 30 20
E-mail: michael.brobjer@arocell.com

About Thymidine Kinase 1

Thymidine Kinase 1 (TK1) is a key enzyme in DNA precursor synthesis. It is up-regulated during the S phase of the cell cycle and degraded in mitosis. Its presence in cells indicates active cell proliferation. Increased levels of TK1 in the blood can indicate abnormal cell turnover or disruption of cells in active proliferation triggered by, for example, therapeutic agents.

About TK 210 ELISA

AroCell TK 210 ELISA is a quantitative immunoassay kit for the determination of Thymidine Kinase 1 (TK1) in human blood. The ELISA format is simple and robust, requires no special instrumentation to perform and can easily be incorporated into standard laboratory processes. By utilizing monoclonal antibodies specific for the TK1 epitope TK 210, AroCell TK 210 ELISA brings improved sensitivity and specificity to the assay of this key biomarker. AroCell TK 210 ELISA provides new opportunities for studying cellular proliferation, disruption, and monitoring of therapy response and relapse in subjects with haematological and solid tumours.

About AroCell

AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein concentrations in a blood sample. The TK 210 ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North Growth Market with Redeye AB as Certified Adviser: Certifiedadviser@redeye.se, +46 (0)8 121 576 90. For more information; www.arocell.com

Attachments

AACR 2020: Posters on TK1 and AroCell TK 210 ELISA is now online